[Initial results in tumor diagnosis with radioactive lanthanide complexes].
Clinical investigations have been made in 70 patients to determine whether 169Yb-labelled metal ligand complexes accumulate in various tumors as was shown by previous animal experiments. The time course of these radiopharmaceuticals in tumors, the skeleton and the liver permitted a good to excellent tumor imaging in 61/70 cases. Even 2-5 h after intravenous injection of the radioactive compound, a meaningful diagnosis could be made in the majority of cases. A number of lesions were found for which no equivalent findings were available with other methods. They were therefore interpreted as metastases.
Franke
W G
WG
Klinik und Poliklinik für Nuklearmedizin, Medizinische Akademie Dresden, FRG.
Schmiedel
T
T
Grundmann
A
A
Pöpel
U
U
Pöpel
U
U
Schomäcker
K
K
Gössel
J
J
D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008674:Metals, Rare Earth; D009369:Neoplasms / Q000000981:diagnostic imaging*; D011868:Radioisotopes; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging; D015899:Tomography, Emission-Computed, Single-Photon; D015018:Ytterbium
D008674:Metals, Rare Earth; D011868:Radioisotopes; D015018:Ytterbium